From Financial Modeling Prep: 2025-04-16 15:57:00

BofA Securities maintains Underperform rating on Hims & Hers Health (NYSE:HIMS) with $22 price target due to slowing momentum. Shares down over 10% intra-day. Q1 online revenue expected to exceed estimates, but March data shows significant slowdown. Average transaction value drops, GLP-1 sales decline in March. Core growth estimated around 35% year-over-year. Concerns raised about achieving $725 million weight loss target by 2025.



Read more at Financial Modeling Prep:: BofA Maintains Bearish Stance on Hims & Hers Amid …